09/18/23 6:30 AMNasdaq : NUVL conferencesclinical trialNuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC SymposiumNuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1...RHEA-AInegative
09/05/23 6:30 AMNasdaq : NUVL clinical trialNuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid TumorsNuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the initiation of the Phase 2 portion of...RHEA-AIneutral
08/31/23 6:30 AMNasdaq : NUVL conferencesNuvalent to Participate in Upcoming September Investor ConferencesNuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in fireside chats during the...RHEA-AIneutral
08/10/23 6:30 AMNasdaq : NUVL earningsNuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial ResultsNuvalent, Inc., a clinical-stage...RHEA-AIneutral
08/01/23 6:30 AMNasdaq : NUVL conferencesNuvalent to Participate in Upcoming August Investor ConferencesNuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in the following August...RHEA-AIneutral
05/24/23 6:30 AMNasdaq : NUVL conferencesNuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation SummitNuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the...RHEA-AIneutral
05/11/23 6:30 AMNasdaq : NUVL earningsclinical trialNuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial ResultsNuvalent, Inc., a clinical-stage...RHEA-AIneutral
04/19/23 6:30 AMNasdaq : NUVL conferencesNuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology DaysNuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Stifel 2023 Virtual Targeted Oncology...RHEA-AIneutral
04/18/23 9:00 AMNasdaq : NUVL clinical trialNuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data supporting theRHEA-AIneutral
03/23/23 6:30 AMNasdaq : NUVL conferencesNuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation for the ongoing Phase 1/ 2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655. The poster will be archived on the Nuvalent website at...RHEA-AIneutral